1 Title

2	Artemether-lumefantrine with or without single-dose primaquine and sulfadoxine-						
3	pyrimethamine plus amodiaquine with or without single-dose tafenoquine to reduce						
4	Plasmodium falciparum transmission: a phase 2 single-blind randomised clinical trial in						
5	Ouelessebougou, Mali.						
6	Almahamoudou Mahamar, PhD ^{1*} , Merel Smit, MD ^{2*} , Koualy Sanogo, MD ¹ , Youssouf Sinaba, MD ¹ ,						
7	Sidi M. Niambele, PharmD ¹ , Adama Sacko, MS ¹ , Oumar M Dicko, MD ¹ , Makonon Diallo, MD ¹ ,						
8	Seydina O Maguiraga, MD ¹ , Yaya Sankaré, MD ¹ , Sekouba Keita, MS ¹ , Siaka Samake, Pharm D ¹ ,						
9	Adama Dembele, MS ¹ , Kjerstin Lanke, PhD ² , Rob ter Heine, PhD ³ , John Bradley, PhD ⁴ , Yahia						
10	Dicko, MD ¹ , Sekou F. Traore, PhD ¹ , Chris Drakeley, PhD ^{5*} , Alassane Dicko, MD ^{1*} , Teun Bousema,						
11	PhD ^{2*} , Will Stone, PhD ^{5*}						
12	¹ Malaria Research and Training Centre, Faculty of Pharmacy and Faculty of Medicine and Dentistry,						
13	University of Sciences Techniques and Technologies of Bamako, Bamako, Mali						
14	² Department of Medical Microbiology and Radboud Center for Infectious Diseases, Radboud						
15	University Medical Center, Nijmegen, the Netherlands						
16	³ Department of Pharmacy and Radboud Center for Infectious Diseases, Radboud University						
17	Medical Center, University of Nijmegen, Nijmegen, the Netherlands						
18	⁴ MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical						
19	Medicine, London, UK						
20	⁵ Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK,						
21	WC1E7HT						
22	*Authors contributed equally						

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1

- 23 Keywords: Gametocytes, Artemether-lumefantrine, Primaquine, Sulfadoxine-pyrimethamine plus
- 24 amodiaquine, Tafenoquine, Transmission-blocking
- **25 Running title:** Transmission-blocking efficacy of AL and SPAQ with PQ and TQ
- 26 Corresponding author: Almahamoudou Mahamar: almahamar@icermali.org
- 27 Alternate corresponding author: Alassane Dicko: adicko@icermali.org

28

29	Brief summary: Sulfadoxine-pyrimethamine plus amodiaquine is commonly used for seasonal
30	malaria chemoprevention. Artemether-lumefantrine is the most widely used treatment regimen for
31	uncomplicated Plasmodium falciparum malaria, but studies to date have shown inconsistent activity of
32	artemether-lumefantrine against P. falciparum gametocytes. This study shows considerable post-
33	treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine but near complete
34	prevention of mosquito infection after artemether-lumefantrine, even without primaquine. The
35	addition of 8-aminoquinolines reduced transmission with both combinations.
36	

38 Summary

39 Background: Artemether-lumefantrine is widely used for uncomplicated Plasmodium falciparum 40 malaria; sulfadoxine-pyrimethamine plus amodiaquine is used for seasonal malaria chemoprevention. 41 We determined the efficacy of artemether-lumefantrine with and without primaguine and 42 sulfadoxine-pyrimethamine plus amodiaquine with and without tafenoquine for reducing gametocyte 43 carriage and transmission to mosquitoes. 44 Methods: In this phase 2, single-blind, randomised clinical trial conducted, asymptomatic 45 individuals aged 10-50 years with P. falciparum gametocytaemia were randomised (1:1:1:1) to receive 46 either artemether-lumefantrine, artemether-lumefantrine with a single dose of 0.25 mg/kgprimaquine, sulfadoxine-pyrimethamine plus amodiaquine or sulfadoxine-pyrimethamine plus 47 48 amodiaquine with a single dose of 1.66 mg/kg tafenoquine. All trial staff other than the pharmacist 49 were blinded. The primary outcome was the median within person percent change in mosquito 50 infection rate in infectious individuals from baseline to day 2 (artemether-lumefantrine groups) or 7 51 (sulfadoxine-pyrimethamine plus amodiaquine groups) post treatment, assessed by direct membrane 52 feeding assay. This study is registered withClinicalTrials.gov, NCT05081089. 53 Findings: Between 13 Oct and 16 Dec 2021, 1290 individuals were screened and 80 were enrolled 54 and randomly assigned to one of the four treatment groups (20 per group). In individuals who were 55 infectious before treatment, the median percentage reduction in mosquito infection rate 2 days after 56 treatment was 100% (IQR 97.2-100; n=19, p=0.026) with artemether-lume fantrine and 100% (100-57 100; n=19, p=0.0001) with artemether-lumefantrine with primaguine. Only two individuals infected 58 mosquitoes on day 2 after artemether-lumefantrine and none at day 5. In contrast, the median 59 percentage reduction in mosquito infection rate 7 days after treatment was 63.60% (IQR 0.62 to

- 60 100, n=20, p=0.009) with sulfadoxine-pyrimethamine plus amodiaquine and 100% (100-100; n=19,
- 61 p < 0.0001) with sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine.
- 62 Interpretation: These data support the effectiveness of artemether-lumefantrine alone for
- 63 preventing nearly all mosquito infections. In contrast, there was considerable post-treatment
- 64 transmission after sulfadoxine-pyrimethamine plus amodiaquine where the addition of a
- 65 transmission-blocking drug may be beneficial in maximizing its community impact.
- 66 Funding: Bill & Melinda Gates Foundation
- 67

69 Introduction

70 Artemisinin-based combination therapies (ACT) retain excellent efficacy for treatment of 71 uncomplicated malaria on the African continent, despite concerning evidence for reduced sensitivity 72 of parasites in East Africa for artemisinins.¹ ACTs rapidly clear asexual parasites but have variable 73 activity against mature gametocytes that are the parasite life stage that can be transmitted to 74 mosquitoes. A pooled analysis of post treatment microscopy data indicated that artemether-75 lumefantrine may be the most potent ACT in terms of gametocyte clearance whilst gametocyte 76 persistence is markedly longer after the drug combination dihydroartemisinin-piperaquine.² 77 Importantly, post-treatment gametocyte carriage is an imperfect approximation of malaria 78 transmission potential. Transmissible gametocytes may persist at submicroscopic densities after 79 treatment and some antimalarial drugs may sterilize gametocytes before these are removed from the 80 circulation.^{3,4} Although artemether-lumefantrine is the most widely used treatment regimen for 81 uncomplicated *Plasmodium falciparum* worldwide,⁵ there are currently no reliable data on malaria 82 transmission post-artemether-lumefantrine. Five studies that performed mosquito feeding assays 83 post-artemether-lumefantrine reached different conclusions. Three studies observed non-negligible 84 transmission between 7 to 14 days after artemether-lumefantrine^{6,7} or artemether-lumefantrine with 85 primaquine⁸ while two others found near complete abrogation of transmission one week after initiation of artemether-lumefantrine treatment without primaquine.^{9,10} The only study that assessed 86 87 transmission to mosquitoes before and after artemether-lumefantrine treatment saw only one 88 individual (2.0%; 1/49) infect mosquitoes at day 7 after treatment initiation, with mosquito infection 89 rates markedly reduced compared to pre-treatment.9 Quantifying post-treatment transmission 90 potential after the most commonly used antimalarial is highly relevant: if there is substantial 91 transmission after treatment with artemether-lumefantrine, the addition of a specific gametocytocide 92 may be considered. The WHO recommends that to reduce onward transmission of *P. falciparum*,

93	ACTs may be combined with a single low-dose of primaquine (0.25 mg/kg) , ¹¹ which has potent but
94	short lived gametocytocidal activity. Although this recommendation is currently limited to areas of
95	low transmission, it has received new relevance in sub-Saharan Africa since the emergence of
96	artemisinin resistance on the African continent. ¹² As a <i>P. falciparum</i> gametocytocide, a single low-dose
97	of 0.25 mg/kg primaquine when combined with ACTs causes an immediate and effective reduction
98	in the transmission of parasites ^{13,14} and is safe for use without prior glucose-6-phosphate
99	dehydrogenase (G6PD) status testing. ¹⁵ It is currently unclear whether the addition of primaquine to
100	artemether-lumefantrine is beneficial or whether artemether-lumefantrine already sufficiently
101	prevents post-treatment transmission.
102	In addition, a recent study with tafenoquine, which is being developed as longer-lasting alternative to
103	primaquine for preventing P. vivax relapse ¹⁶ demonstrated that a single low-dose of tafenoquine
104	(1.66 mg/kg) in combination with dihydroartemisinin-piperaquine completely prevented infectivity
105	within 7 days after initiation of treatment in Malian adults and children. ¹⁷ Though this trial showed
106	that tafenoquine can prevent transmission when co-administered with dihydroartemisinin-
107	piperaquine, the effect appeared to be slower than primaquine. ¹⁸ Recent observations that
108	Indonesian soldiers given dihydroartemisinin-piperaquine with or without 300 mg tafenoquine
109	showed similar rates of <i>P. vivax</i> relapse, ¹⁹ suggest that dihydroartemisinin-piperaquine may negatively
110	impact tafenoquine efficacy. The combination of tafenoquine with non-ACTs to clear P. falciparum
111	gametocytes and prevent transmission has not been tested. Sulfadoxine-pyrimethamine plus
112	amodiaquine is a non-artemisinin based combined anti-malarial treatment that is the only
113	antimalarial recommended for systematic mass administration in the form of seasonal malaria
114	chemoprevention (SMC). ²⁰ Prior studies showed considerable post-treatment transmission potential
115	following sulfadoxine-pyrimethamine plus amodiaquine with infectivity and mosquito infection rate
116	unaffected for the first 7 days post-treatment and reductions in gametocytaemia only observed after

117	28 days. ^{7,14} Increased gametocyte densities in the first 2 weeks following sulfadoxine-pyrimethamine
118	plus amodiaquine will limit any effect of SMC on transmission.7 The combination of sulfadoxine-
119	pyrimethamine plus amodiaquine with a single low-dose tafenoquine has never been tested.
120	In the current study, we assessed the two widely used malaria treatments in combination with single
121	low-dose of gametocytocidal, transmission-blocking drugs in Malian children and adults.

122 Methods

123 Study design and participants

124 This four-arm, single-blind, phase 2 randomised controlled trial was conducted at the

125 Ouelessebougou Clinical Research Unit of the Malaria Research and Training Centre (MRTC) of the

126 University of Bamako in Mali. Before the commencement of screening, the study team met with

127 community leaders, village health workers, and heads of households from each village to explain the

128 study and obtain approval to conduct the study. Village health workers then used a door-to-door

approach to inform households of the date and location where consenting and screening would take

130 place. Participants were included in the trial if they met the following criteria: positive for *P*.

131 *falciparum* gametocytes by microscopy (i.e. ≥ 1 gametocytes recorded in a thick film against 500 white

132 blood cells, equating to 16 gametocytes/ μ L with a standard conversion of 8000 white blood cells

133 (WBC)/µL blood); absence of other non-*P. falciparum* species on blood film; haemoglobin density of

134 $\geq 10 \text{ g/dL}$; G6PD normal (male >4 IU/g Hb, female >6 IU/g Hb); aged between 10-50 years;

bodyweight of ≤ 80 kg; no clinical signs of malaria, defined by fever ($\geq 37.5^{\circ}$ C); no signs of acute,

136 severe or chronic disease; consistent with the long half-life of tafenoquine, use of effective

137 contraception for 5 half-lives (3 months) after the end of tafenoquine treatment. Exclusion criteria

138 included pregnancy (tested at enrolment by urine test) or lactation, allergies to any of the study

139 drugs, use of other medication (except for paracetamol and/or aspirin), use of antimalarial drugs

- 140 over the past week, family history of congenital prolongation of the corrected QT (QTc) interval,
- 141 current/recent treatment with drugs known to extend QTc interval, and blood transfusion in last 90
- 142 days. Prior to screening and prior to study enrolment, participants provided written informed
- **143** consent (\geq 18 years) or assent with written parental consent (10-17 years).
- 144 Ethical approval was granted by the Ethics Committee of the Faculty of Medicine, Pharmacy, and
- 145 Dentistry of the University of Science, Techniques, and Technologies of Bamako (Bamako, Mali)
- 146 (N°2021/189/CE/USTTB), and the Research Ethics Committee of the London School of Hygiene
- and Tropical Medicine (London, United Kingdom) (LSHTM Ethics Ref: 26257).

148 Randomisation and masking

- 149 Allocation to four treatment groups (artemether-lumefantrine, artemether-lumefantrine with
- 150 primaquine [0.25 mg/kg], sulfadoxine-pyrimethamine plus amodiaquine, and sulfadoxine-
- 151 pyrimethamine plus amodiaquine with tafenoquine [1.66 mg/kg] was randomised in a 1:1:1:1 ratio.
- 152 Enrolment continued until 80 participants were enrolled (20 individuals assigned to each treatment
- 153 group). An independent MRTC statistician randomly generated the treatment assignment using Stata
- 154 version 16 (StataCorp, College Station, Texas, USA), which was linked to participant ID number.
- 155 The statistician prepared sealed, opaque envelopes with the participant ID number on the outside
- **156** and treatment assignment inside which were sent to the MRTC study pharmacist. The study
- 157 pharmacist provided treatment and was consequently not blinded to treatment assignment; staff
- **158** involved in assessing safety and laboratory outcomes were blinded.

159 Procedures

- 160 Artemether-lumefantrine treatment (Coartem, Novartis, Basel, Switzerland) was administered over
- 161 three days as per manufacturer instructions (appendix pp. 2). A single dose of 0.25 mg/kg
- 162 primaquine was administered on day 0 in parallel with the first dose of artemether-lumefantrine as

163	described previously (ACE Pharmaceuticals, the Netherlands). ¹⁴ Participants in the sulfadoxine-
164	pyrimethamine plus amodiaquine groups were treated with standard doses of sulfadoxine-
165	pyrimethamine plus amodiaquine (Guilin Pharmaceutical (Shanghai) Co., Ltd. Rm. 701, 780 Cailun
166	Rd., Zhangjiang Hi Tech Park, Shanghai, 201203 China) as per manufacturer instructions (appendix
167	pp. 2). A single dose of tafenoquine (Arakoda, 60° pharmaceuticals LLC, DC, USA) was
168	administered on day 0 in parallel with the first doses of sulfadoxine-pyrimethamine and
169	amodiaquine. Tafenoquine dosing was weight based to standardise efficacy and risk variance
170	(appendix pp. 3). The dose of 1.66 mg/kg chosen for the study was based on good safety profile
171	and efficacy in Malian adults and children ≥12 years old. ¹⁷ G6PD testing was conducted using both
172	semi-quantitative (OSMMR-D G-6-PD test; R&D Diagnostics, Aghia Paraskevi, Greece) and
173	quantitative testing (STANDARD TM G6PD Test, SD BIOSENSOR, Suwon, South Korea);
174	inclusion in the study required normal enzyme function to be determined by both methods.
175	Participants received a full clinical and parasitological examination on days 2, 5, 7, 14, 21, and 28
176	after receiving the first dose of the study drugs (appendix pp. 3). Giemsa stained thick film
177	microscopy was performed as described previously, with asexual stages counted against 200 WBC
178	and gametocytes counted against 500 WBC. ¹⁴ For molecular gametocyte quantification, total nucleic
179	acids were extracted using a MagNAPure LC automated extractor (Total Nucleic Acid Isolation Kit-
180	High Performance; Roche Applied Science, Indianapolis, IN, USA). Male and female gametocytes
181	were quantified in a multiplex reverse transcriptase quantitative PCR (RT-qPCR) assay (appendix pp.
182	4). ²¹ Samples were classified as negative for a particular gametocyte sex if the qRT-PCR quantified
183	density of gametocytes of that sex was less than 0.01 gametocytes per μ L (i.e. one gametocyte per
184	100 µL of blood sample). Haemoglobin density was measured using a haemoglobin analyser
185	(HemoCue; AB Leo Diagnostics, Helsingborg, Sweden) or automatic haematology analyser
186	(HumaCount 5D; Wiesbaden, Germany). Additional venous blood samples were taken for

187 biochemical and infectivity assessments on day 0, 2, 5, 7, and 14 in all treatment groups. Aspartate 188 transaminase (AST), alanine transaminase (ALT) and blood creatine levels were determined using 189 automatic biochemistry analyser Human 100 (Wiesbaden, Germany). For each assessment of 190 infectivity, ~75 locally reared female Anopheles gambiae mosquitoes were allowed to feed for 15-20 191 minutes on venous blood samples (Lithium Heparin VACUETTE tube, Greiner Bio-One, 192 Kremsmünster, Austria) through a prewarmed glass membrane feeder system (Coelen Glastechniek, Weldaad, the Netherlands). Surviving mosquitoes were dissected on the 7th day after feeding; 193 194 midguts were stained in 1% mercurochrome and examined for the presence and density of oocysts 195 by expert microscopists. Adverse events (AE) were graded by the study clinician for severity (mild, 196 moderate, severe) and relatedness to study medication (unrelated or unlikely, possibly, probably, or 197 definitely related). A drop in haemoglobin concentration of $\geq 40\%$ from baseline was categorised as 198 a haematological severe AE. An external data safety and monitoring committee was assembled prior 199 to the trial, and safety data was discussed after enrolment of 40 participants, and after the final 200 follow-up visit of the last participant.

201 Data analysis

Sample size estimation was based on infectivity for participants in previous trials in the same study
setting using a mixed effects logistic regression model that accounted for correlation between
mosquito observations from the same participant.^{13,14,17,18} With an expected reduction in infectivity of
90% as previously detected for efficacious doses of primaquine and tafenoquine,^{14,17,18} we calculated
92% empirical power to detect >85% reduction in infectivity with a one-tailed test with an α=0.05
level of significance when including 20 participants and dissecting 50 mosquitoes at each time point.
When using an α=0.025, empirical power was calculated at 90%.

209 Clinical and entomological data were double entered into a MS Access database and analysed using 210 STATA (version 16.0) and SAS (version 9.4). Statistical analyses of mosquito infection rate and 211 oocyst density were analysed at timepoints after baseline only for those individuals who were 212 infectious at baseline. The prevalence of gametocytes and infectious individuals were compared 213 within and between treatment groups using one-sided Fishers exact tests. Haemoglobin levels were 214 compared using paired t tests (t score) for within-group analyses and linear regression adjusted for 215 baseline levels of each measure for between-group analyses (t score, coefficient with 95% CI). 216 Percentage change from baseline was analysed using two-way t tests. The proportion of gametocytes 217 that were male was analysed for all values with total gametocyte densities of 0.2 gametocytes per μL or more.¹⁴ Gametocyte circulation time was calculated to determine the mean number of days that a 218 219 mature gametocyte circulates in the blood before clearance, using a deterministic compartmental 220 model that assumes a constant rate of clearance and has a random effect to account for repeated measures on individuals, as described previously;²² difference in circulation time between groups and 221 222 between gametocyte sexes was analysed using t tests (t score). Area under the curve (AUC) of 223 gametocyte density per participant over time was calculated using the linear trapezoid method and 224 was analysed by fitting linear regression models to the log₁₀ adjusted AUC values, with adjustment 225 for baseline gametocyte density (t score, coefficient with 95% CI). All other analyses of quantitative 226 data were done using Wilcoxon sign rank tests (z-score) and Wilcoxon rank-sum tests (z-score). All 227 comparisons were defined before study completion and analyses were not adjusted for multiple 228 comparisons. For all analyses, the threshold for statistical significance was set at p < 0.05. The trial is 229 registered with ClinicalTrials.gov, NCT05081089.

230 Role of funding source

231 The funder of the study had no role in study design, data collection, data analysis, data

232 interpretation, or writing of the report.

Between 13 Oct and 16 Dec 2021, 1290 individuals were assessed for eligibility and 80 were enrolled

233 **Results**

235 and randomly assigned to one of the four treatment groups (n=20 per group) of which 77 (96%) 236 completed all follow-up visits (figure 1). Participant baseline characteristics were similar between the 237 study groups (table 1). 238 Before treatment, 61 (76%) of 80 participants were infectious to mosquitoes, with a median of 5.5% 239 (IQR 1·4–15·5) of mosquitoes becoming infected (table 2; appendix pp. 5). At day 2, 2 (11%) of 19 240 participants in the artemether-lumefantrine group and 0 (0%) of 19 participants in the artemether-241 lumefantrine with primaguine group infected mosquitoes (figure 2). In individuals who were 242 infectious before treatment, the median percentage reduction in mosquito infection rate 2 days after 243 treatment was 100% (IQR 97.2 to 100) for individuals treated with artemether-lumefantrine (n=19; p=0.026) and 100% (IQR 100 to 100) with artemether-lumefantrine with primaquine (n=19; 244 245 p=0.0001). One participant who received artemether-lumefantrine was infectious on day 5, but not 246 infectious on day 0 or 2. Furthermore, there was one participant in the artemether-lumefantrine with 247 primaguine group who was infectious at baseline and at day 5, but not at day 2. At day 7, 11 (55%) 248 of 20 participants in the sulfadoxine-pyrimethamine plus amodiaquine group and 0 (0%) of 19 249 participants in the sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine group infected 250 any number of mosquitoes. In individuals who were infectious before treatment, the median 251 percentage reduction in mosquito infection rate 7 days after treatment was 63.6% (IQR 0.62 to 100) 252 for individuals treated with sulfadoxine-pyrimethamine plus amodiaquine (n=11; p=0.0090) 253 compared with 100% (IQR 100 to 100) with sulfadoxine-pyrimethamine plus amodiaquine with 254 tafenoquine (n=19; p<0.0001).

255	The median reduction in mosquito infection rate in the artemether-lumefantrine group was not
256	significantly different from the artemether-lumefantrine with primaquine group at any timepoint. No
257	mosquito infections were observed after day 5 in either artemether-lumefantrine treatment groups.
258	In the sulfadoxine-pyrimethamine plus amodiaquine and sulfadoxine-pyrimethamine plus
259	amodiaquine with tafenoquine groups respectively, 14 (70%) of 20 and 14 (74%) of 19 individuals
260	were infectious to mosquitoes at day 2, while 15 (75%) of 20 and 1 (5%) of 19 were infectious at day
261	5. Median reduction in mosquito infection rate in individuals infectious at baseline was significantly
262	different between arms by day 5, when there was a 19.29% (IQR 48.13 to 78.96) reduction in the
263	sulfadoxine-pyrimethamine plus amodiaquine group, and near total abrogation of infection with the
264	addition of tafenoquine (100%, IQR 100 to 100) (table 2).
265	Gametocyte densities declined after initiation of treatment in all treatment groups, although the
266	decrease was much less rapid in the sulfadoxine-pyrimethamine plus amodiaquine group (figure 3;
267	appendix pp. 7-8); 20 (100%) of 20 participants treated with sulfadoxine-pyrimethamine plus
268	amodiaquine alone were still gametocyte positive at the final day of observation (day 28), compared
269	with 11 (58%) of 19 after artemether-lumefantrine alone. Total gametocyte circulation time was
270	estimated at 5.3 days (95% CI 4.5-6.0) in the artemether-lumefantrine group and 2.9 days (2.4-3.3)
271	in the artemether-lumefantrine with primaquine group (appendix pp. 6); the same measure was
272	estimated at 9.1 days (7.3-11.0) and 3.3 days (2.9-3.6) in the sulfadoxine-pyrimethamine plus
273	amodiaquine and sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine groups
274	respectively. Gametocyte sex ratios were initially similar in all treatment groups, but the ratio
275	increased towards male in the artemether-lumefantrine group from day 2 after treatment (median
276	proportion of male gametocytes 0.46 [IQR 0.37-0.51] on day 0 and 0.80 [0.60-0.92] (p=0.013) on
277	day 2) (appendix pp. 7-9). In the sulfadoxine-pyrimethamine plus amodiaquine group, sex ratios
278	remained largely unchanged but with an increasing bias toward females over the 28-day trial period.

279	Treatment with primaquine (p= 0.0023) resulted in significantly male-biased ratios from day 2						
280	(p=0.0023), while male bias due to takenoquine was significant from day 5 (p<0.0001). The absolute						
281	infectivity of persisting gametocytes was significantly lower in the sulfadoxine-pyrimethamine plus						
282	amodiaquine with tafenoquine group than in the sulfadoxine-pyrimethamine plus amodiaquine						
283	group (day 2 odds-ratio (OR) 0.59, p<0.0001; day 5 OR 0.0077, p<0.0001), whereas in the						
284	artemether-lumefantrine groups too few gametocytes persisted to allow this comparison (appendix						
285	pp. 10).						
200							

286 There were no haemolytic severe adverse events (drop of >40% from baseline). Transient

reductions in haemoglobin density were greater in the sulfadoxine-pyrimethamine groups than in the

artemether-lumefantrine groups, with significant reductions in haemoglobin density observed at day

289 1 and 2 (during the period of treatment administration) in both sulfadoxine-pyrimethamine plus

amodiaquine groups (mean change between -4.99% and -6.35%); these resolved by day 5 (appendix

291 pp. 11-12). The maximum drop in haemoglobin between baseline and any study timepoint was

292 15.4% in the artemether-lumefantrine group, 15.9% in the artemether-lumefantrine with primaquine

293 group, $24 \cdot 3\%$ in the sulfadoxine-pyrimethamine plus amodiaquine group and $23 \cdot 5\%$ in the

sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine group.

295 Overall, 50 (62.5%) of the 80 participants experienced a total of 92 adverse events during follow-up,

of which 61 were at least possibly related to the study drugs. 48 (79%) of the at least possibly related

adverse events which were categorised as mild and 13 (21%) as moderate. No grade 3 or serious

adverse events occurred (table 3). The most common adverse events were headaches, abdominal

299 pain, and nausea. No severe laboratory abnormalities occurred; all possibly drug related laboratory

abnormalities normalised on the subsequent visit (appendix pp. 13).

301 Discussion

302 In this randomised clinical trial, we determined the gametocytocidal and transmission-blocking 303 activities of 1) the most widely used first-line antimalarial, artemether-lumefantrine, with and without 304 the WHO recommended single low-dose of 0.25 mg/kg of primaguine, and 2) the preferred chemo-305 preventative treatment, sulfadoxine-pyrimethamine plus amodiaquine, with and without a single 306 dose of 1.66 mg/kg tafenoquine. Artemether-lumefantrine alone blocked almost all transmission 307 within 2 days of treatment initiation, whereas sulfadoxine-pyrimethamine plus amodiaquine had 308 limited effect on gametocyte density and prevalence, with significant reductions in infectivity to 309 mosquitoes only observed after 14 days. While the addition of tafenoquine did not prevent 310 transmission at day 2 after treatment initiation, no infected mosquitoes were observed at the next 311 mosquito feeding timepoint on day 5. 312 Calls for malaria eradication and concerns about the spread of drug resistance have increased 313 interest in the effects of antimalarial drugs on gametocytes and their infectiousness.²³ Since 314 transmission cannot be reliably predicted from gametocyte densities and direct mosquito 315 transmission outcomes are technically challenging, assessments of post-treatment infectiousness 316 have been few and inconsistent. Previous studies demonstrated that the gametocytocidal effect of 317 artemether-lumefantrine is superior to that of other ACTs like dihydroartemisinin-piperaquine and pyronaridine-artesunate,^{24,25} but were inconclusive on its ability to prevent transmission to 318 mosquitoes early after treatment.⁶⁻¹⁰ In a selected population with high gametocyte densities and 319 320 confirmed transmission potential prior to treatment, we demonstrate that artemether-lumefantrine 321 exerts a strong gametocytocidal and transmission-blocking effect. Our finding of a median within-322 person reduction in mosquito infection rate of 100% 2 days after artemether-lumefantrine treatment corroborates findings from clinical trials in Kenya and Gambia.^{6,10} Gametocyte densities also 323 324 declined after artemether-lumefantrine, total gametocyte density dropped by 44% (38.44 [IQR 9.15-325 56.47] to 21.61 [7.51-44.01] gametocytes/µL) between baseline and day 2. However, participants

326	were still carrying transmissible densities of gametocytes at day 2, ²⁰ which suggests that the reduction
327	in infectivity was due to sex ratio distortion and/or a sterilising effect. ⁴

- 328 The potent transmission-blocking effect artemether-lumefantrine contrasts with pyronaridine-
- 329 artesunate and dihydroartemisinin-piperaquine for which significant reductions in mosquito
- infection rate were only seen from days 10 and 7-14 days post-treatment respectively, when tested in

331 the same facilities.^{17,18} Also for individuals treated with sulfadoxine-pyrimethamine plus

amodiaquine, considerable and prolonged post-treatment transmission was observed; 69% (11/16)

333 of individuals infectious to mosquitoes at baseline were still infectious a week later, and three weeks

after treatment 19% (3/16) remained infectious. These data align with prior observations that show

no change in transmission potential in the week following sulfadoxine-pyrimethamine plus

amodiaquine treatment.¹⁴ Male and female gametocyte density declined initially and then increased

337 slightly at day 5; these transient increases in gametocyte density following sulfadoxine-

338 pyrimethamine plus amodiaquine have been observed previously.⁷ Here, 50% (n/N = 10/20) of

individuals had more gametocytes at day 5 than at day 2 (compared to 5.3-15.8% in other treatment

340 groups) which corresponded to increased infectiousness over the same time frame. Unlike in the

341 artemether-lumefantrine groups, treatment with sulfadoxine-pyrimethamine plus amodiaquine did

not cause any distortion in sex ratio, and though gametocyte prevalence remained at $\geq 90\%$

343 throughout the study, densities declined in the majority of into low likely untransmissible levels in

the majority of participants by 21 days post treatment.²⁶

345 As expected, treatment the addition of a single low-dose of tafenoquine to sulfadoxine-

346 pyrimethamine plus amodiaquine resulted in significant transmission-blocking activity among study

347 participants. These results are consistent with previous studies in this setting, where the same low-

- 348 dose of tafenoquine (1.66 mg/kg) added to dihydroartemisinin–piperaquine led to complete
- 349 transmission blockade at 7 days post-treatment.¹⁷ Recent studies have shown sub-optimal *P. vivax*

350	relapse rates after tafenoquine radical cure when co-administered with dihydroartemisnin-
351	piperaquine. ²⁷ The reasons for this are unknown, but the combination appears effective for P .
352	falciparum transmission blockade, albeit with a delayed effect compared to primaquine. ¹⁷ The current
353	study, observing a similar timing of the transmission blocking effect when combined with a non-
354	ACT, argues against a putative artemisinin specific antagonism/interaction as the cause of the
355	delayed effect. ²⁷ In a controlled human malaria infection trial, the transmission-blocking efficacy of a
356	single 50 mg dose of tafenoquine showed modest reduction of mosquito infection rate at day 4 of
357	35% and 81% by day 7. ²⁸ This dose is approximately half of that given in the current trial (1.66
358	mg/kg) which resulted in a median reduction in mosquito infection rate of 100% (IQR 100-100),
359	while participant infectivity dropped from 70% (n/N=14/20) to 10% (n/N=2/20). ¹⁷
360	Although it is likely to have a prolonged transmission-blocking, there remain concerns for the safely
361	of tafenoquine in G6PD deficient individuals. Testing for G6PD deficiency is required before
362	administration of tafenoquine for its current indications in treatment of P. vivax (i.e. 200 mg daily for
363	3 days or single 300 mg dose). ²⁹ This study enrolled only G6PD normal individuals, to ensure
364	comparability between groups. We observed no haematological, grade 3, or serious adverse events in
365	any treatment arm, and transient reductions in haemoglobin density that were not significantly
366	different between groups with and without 8-aminoquinonlines. Our results reinforce the previous
367	observations that single low-doses of primaquine and tafenoquine are safe and well tolerated but
368	data for tafenoquine in G6PD deficient individuals are needed.
369	Because the primary outcome of the current trial was P. falciparum transmission and consistent with
370	previous studies, high-density gametocyte carriers were recruited. With the assessment of infectivity
371	before and after treatment, our findings are highly informative on the transmission-reducing activity
372	of the tested drugs among highly infectious individuals. However, different study populations are
373	required for assessments of community level benefits of antimalarials combined with 8-

374 aminoquinolines when given according to WHO guidelines (i.e at clinical presentation) or in mass 375 treatment campaigns, including SMC. Moreover, our finding that single low dose primaguine 376 appears to have little added benefit on reducing transmission when given with artemether-377 lumefantrine, needs to be considered in the light of possible use scenarios. Alternative ACTs with 378 larger post-treatment transmission potential such as dihydroartemisinin-piperaquine are typically 379 used in community treatment campaigns and the relevance of primaquine is likely to be larger. 380 Moreover, gametocytes in *P*[*Kelch13* mutant infections may preferentially survive artemisinin 381 exposure and infect mosquitoes.³⁰ The addition of a non-artemisinin gametocytocide (such as PQ or 382 TQ) to standard treatment may thus be a valuable tool to limit the spread of artemisinin partial 383 resistance in Africa; the WHO malaria policy and advisory group suggested the broader adoption of 384 single low dose primaquine in countries where partial resistance has been detected.¹² 385 In conclusion, our findings show that artemether-lumefantrine has intrinsic ability to prevent nearly 386 all mosquito infections, even without primaguine, with good safety profile and reveal considerable 387 post-treatment transmission after sulfadoxine-pyrimethamine plus amodiaquine. The addition of a 388 transmission-blocking drug may be beneficial in maximising the community benefit of seasonal 389 malaria chemoprevention. 390

391 Funding

This work was supported by the Bill and Melinda Gates Foundation (#INV-002098). Under the
grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has
already been assigned to the Author Accepted Manuscript version that might arise from this
submission. TB and KJL are further supported by supported by the European Research Council
(ERC-CoG 864180; QUANTUM). WS is supported by a Wellcome Trust fellowship
(218676/Z/19/Z/WT).

398 Contributors

- 399 WS, AM, MS, MM, TB, CD, and AD conceived the study and developed the study protocol. WS,
- 400 AM, MS, KS, YSi, SMN, AS, OMD, MD, SOM, YSa, SK, YD, SFT, AD, TB, CD, and AD
- 401 implemented the trial. KL performed molecular analyses. WS, MS and AM verified the raw data.
- 402 MS, WS and JB analysed the data. WS, AM, MS, RtH, JB, TB, CD, and AD wrote the first draft of
- 403 the manuscript. All authors read and approved the final manuscript.

404 Declaration of interests

405 We have no competing interests.

406 Data sharing

407 Anonymised data reported in the manuscript will be made available to investigators who provide a408 methodologically sound proposal to the corresponding author. The protocol is available upon

409 request.

410 Acknowledgments

411 Primaquine tablets were kindly donated by ACE Pharmaceuticals, Zeewolde, the Netherlands.

412 Tafenoquine tablets were kindly donated by 60° Pharmaceuticals Ltd, USA. We would like to thank

413 the study participants and the population of Ouelessebougou, Mali for their cooperation. Finally, we

- 414 would like to thank the local safety monitor, members of the data safety and monitoring board for
- their assistance.

416

418 Figure legends

419	Figure 1. Screening and recruitment profile. 77 of 80 participants completed all follow-up visits:						
420	one in the artemether-lumefantrine group, one in the artemether-lumefantrine with primaquine						
421	group and one in the sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine group did not						
422	complete all visits.						
423	Figure 2. Participant infectivity and proportion of mosquitoes infected in direct membrane						
424	feeding assays. Before treatment, 76% of participants were infectious to mosquitoes, infecting a						
425	median of 9.7% of mosquitoes. By day 2, the median within-person reduction in mosquito infection						
426	rate following AL and AL+PQ was 100%. Transmission-blocking effects in sulfadoxine-						
427	pyrimethamine plus amodiaquine showed 19.29% reduction in transmission by day 5 compared to						
428	100% for sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine.						
429	Figure 3. Male and female gametocyte density and prevalence. Gametocyte densities decreased						
430	after initiation of treatment in all study groups, although the decrease was less rapid in the						
431	sulfadoxine-pyrimethamine plus amodiaquine alone group. Gametocyte sex ratios were initially						
432	similar in all treatment groups, but female gametocyte density decreased substantially in the						
433	artemether-lumefantrine group by day 5 after treatment, resulting in a significantly male-biased sex						
434	ratio.						

435 Tables

436 Table 1. Baseline characteristics

437

	Artemether- lumefantrine (n=20) Artemether- lumefantrine with primaquine 0.25 mg/kg (n=20)		Sulfadoxine- pyrimethamine plus amodiaquine (n=20)	Sulfadoxine- pyrimethamine plus amodiaquine with tafenoquine 1.66 mg/kg (n=20)	
Age, years	14 (12–19)	12 (10–19)	14 (12–22)	13 (10–20)	
Proportion of female	12 (60%)	7 (35%)	11 (55%)	7 (35%)	
Weight, kg	37.5 (30.0-49.6)	35.5 (27.3-48.3)	46.5 (31.0-58.0)	35.5 (25.0–55.5)	
Haemoglobin, g/dL	11.5 (11.0–12.3)	12.4 (12.0–12.9)	12.4 (11.2–13.3)	12.8 (12.1–14.0)	
Gametocyte prevalence	20 (100%)	20 (100%)	20 (100%)	20 (100%)	
Gametocyte density, parasites per µL	41.3 (9.9–58.4)	30.4 (27.6–92.4)	36.4 (16.1–145.4)	24.5 (7.7–126.0)	
Asexual parasite prevalence	12 (60%)	11 (55%)	12 (60%)	11 (55%)	
Asexual parasite density, parasites per µL	400 (120-2340)	400 (120-1120)	440 (180-2060)	400 (80-2160)	

438 439

439 Data are median (IQR) or n (%). Gametocyte prevalence was assessed by thick film microscopy, and gametocyte density was calculated from reverse transcriptase
 440 quantitative PCR targeting CCP4/PfMGET mRNA (gametocytes). Asexual parasite prevalence and density were assessed by thick film microscopy.

441 Table 2. Infectivity to mosquitoes before and after treatment

	Infectious individuals*	Median mosquito infection rate † (IQR)	Median reduction in mosquito infection rate ‡ (IQR)	P-value §	P-value ¶	
Pretreatment						
Artemether-lumefantrine	13/20 (65%)	9.38% (4.23 - 21.31)		••	••	
Artemether-lumefantrine with primaquine 0.25 mg/kg	16/20 (80%)	9.84% (5.77 - 13.13)				
Sulfadoxine-pyrimethamine plus amodiaquine	16/20 (80%)	9·26% (4·34 - 38·49)				
Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine 1.66 mg/kg	16/20 (80%)	14.80% (3.20 - 20.97)				
Day 2						
Artemether-lumefantrine	2/19 (11%)	2.39% (2.00 - 2.78)	100% (97·2 - 100)	0.026	Reference	
Artemether-lumefantrine with primaquine 0.25 mg/kg	0/19 (0%)		100% (100 - 100)	0.0001	0.15	
Sulfadoxine-pyrimethamine plus amodiaquine	14/20 (70%)	17.98% (3.60 - 30.83)	30.42% (7.16 - 80.37)	0.018	Reference	
Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine 1.66 mg/kg	14/19 (74%)	6.87% (1.66 - 17.57)	67.48% (19.80 -94.17)	0.055	0.33	
Day 5	•	-		•	•	
Artemether-lumefantrine	1/19 (5%)	21.88% (21.88 - 21.88)	100% (100 - 100)	0.0005	Reference	
Artemether-lumefantrine with primaquine 0.25 mg/kg	1/19 (5%)	9·38% (9·38 - 9·38)	100% (100 - 100)	0.0065	1.0	
Sulfadoxine-pyrimethamine plus amodiaquine	15/20 (75%)	15.87% (2.26 - 51.22)	19·29% (48·13 - 70·96)	0.78	Reference	
Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine 1.66 mg/kg	1/19 (5%)	1.45% (1.45 - 1.45)	100% (100 - 100)	<0.0001	<0.0001	
Day 7						
Artemether-lumefantrine	0/19 (0%)		100% (100 - 100)	0.0005	Reference	
Artemether-lumefantrine with primaquine 0.25 mg/kg	0/19 (0%)		100% (100 - 100)	0.0001	1.0	
Sulfadoxine-pyrimethamine plus amodiaquine	11/20 (55%)	12.77% (7.77 -47.40)	63.60% (0.62 - 100)	0.0090	Reference	
Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine 1.66 mg/kg	0/19 (0%)		100% (100 - 100)	<0.0001	0.0001	

442

* Individuals were classed as infectious if direct membrane feeding assays resulted in at least one mosquito with any

444 number of oocysts. Mosquito infection measures (percentage infection and oocyst density) are shown for all participants445 who were infectious at baseline, and oocyst densities are from all infected mosquitoes.

446 † Median proportion of mosquitoes infected by each participant, where for each participant the mosquito infection rate

447 was the number of mosquitoes infected as a proportion of all mosquitoes surviving to dissection.

448 ‡ Median reduction (relative to baseline) in mosquito infection rate at the given timepoints. All values are for individuals

449 who were infectious to mosquitoes before treatment (ie, infected any number of mosquitoes).

450 § Within-group comparison in median reduction in mosquito infection rate (primary outcome).

451 ¶ Between-group comparison in median reduction in mosquito infection rate. Full details of mosquito feeding assay

452 outcomes are in appendix (pp. 5).

453 Table 3. Frequency of adverse events

Description All (n=80)	lumefantrine	Artemether- lumefantrine with	pyrimethamine	Sulfadoxine- pyrimethamine
	(n=20)		plus	plus amodiaquine

			primaquine 0·25 mg/kg (n=20)	amodiaquine (n=20)	with tafenoquine 1.66 mg/kg (n=20)
All	62.5% (50/80)	30% (6/20)	65% (13/20)	80% (16/20)	75% (15/20)
P-value	0.16*		0.056**		1.00**
Mild related AE	36% (29/80)	20% (4/20)	45% (9/20)	50% (10/20)	30% (6/20)
P-value	0.37*		0.176**		0.333**
Moderate related AE	11% (9/80)	0% (0/20)	0% (0/20)	15% (3/20)	30% (6/20)
P-value	0.012*		nc		0.451**
Severe related AE	0% (0/80)	0% (0/20)	0% (0/20)	0% (0/20)	0% (0/20)
P-value	nc		пс		nc

455

456 Number of participants per group who experienced adverse events. If there were multiple episodes per participant, the

457 highest grade is presented in this table. Classification as 'related to treatment' was defined as probably, possibly or

definitely related to treatment, as described in the methods. P-values are from Fisher's exact tests for differences in

proportion of individuals with an AE between all groups* or between AL+PQ group and the (AL) reference group and
 SPAQ+TQ group and the (SPAQ) reference group**.

461 nc = not calculable.

462 References

463

464 1. World Health Organization. Artemisinin resistance and artemisinin-based combination
465 therapy efficacy: status report. , 2018.

466 2. Stepniewska K, Allen EN, Humphreys GS, et al. Safety of single-dose primaquine as a

Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual
patient data. *BMC Med* 2022; **20**(1): 350.

Schneider P, Bousema T, Omar S, et al. (Sub)microscopic Plasmodium falciparum
 gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine

471 monotherapy or in combination with artesunate. *Int J Parasitol* 2006; **36**(4): 403-8.

472 4. Bradley J, Soumare HM, Mahamar A, et al. Transmission-blocking Effects of Primaquine
473 and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than

474 Effects on Sex Ratio. *Clin Infect Dis* 2019; **69**(8): 1436-9.

475 5. World Health Organization. Global Malaria Programma: country antimalarial drug
476 policies (Global AMDP database), 2018.

477 6. Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether-

478 lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. *J Infect Dis* 2013;

479 **207**(11): 1637-45.

480 7. Bousema JT, Schneider P, Gouagna LC, et al. Moderate effect of artemisinin-based
481 combination therapy on transmission of Plasmodium falciparum. *J Infect Dis* 2006; **193**(8):
482 1151-9.

483 8. Mwaiswelo RO, Ngasala B, Msolo D, Kweka E, Mmbando BP, Martensson A. A single low
484 dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum

485 gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district,

486 Tanzania. *Malar J* 2022; **21**(1): 84.

487 9. Goncalves BP, Tiono AB, Ouedraogo A, et al. Single low dose primaquine to reduce488 gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in

children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. *BMC Med* 2016; **14**: 40.

491 10. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to Anopheles
492 mosquitoes with a six-dose regimen of co-artemether. *PLoS Med* 2005; **2**(4): e92.

493 11. World Health Organization. Global Malaria Programme: WHO policy brief on single-dose
494 primaquine as gametocytocide in *Plasmodium falciparum* malaria, 2015.

495 12. Malaria Policy Advisory Group. WHO Malaria Policy Advisory Group (MPAG) meeting496 report, 2023.

497 13. Dicko A, Brown JM, Diawara H, et al. Primaquine to reduce transmission of Plasmodium
498 falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
499 Lancet Infect Dis 2016; 16(6): 674-84.

50014.Dicko A, Roh ME, Diawara H, et al. Efficacy and safety of primaquine and methylene blue501for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind,

randomised controlled trial. *Lancet Infect Dis* 2018; **18**(6): 627-39.

503 15. Bastiaens GJH, Tiono AB, Okebe J, et al. Safety of single low-dose primaquine in glucose504 6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label,
505 randomized, safety trials. *PLoS One* 2018; **13**(1): e0190272.

Hounkpatin AB, Kreidenweiss A, Held J. Clinical utility of tafenoquine in the prevention
of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial
data. *Infect Drug Resist* 2019; **12**: 553-70.

509 17. Stone W, Mahamar A, Smit MJ, et al. Single low-dose tafenoquine combined with 510 dihydroartemisinin-piperaguine to reduce Plasmodium falciparum transmission in

510 Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. *Lancet Microbe* 2022;

512 **3**(5): e336-e47.

51318.Stone W, Mahamar A, Sanogo K, et al. Pyronaridine-artesunate or dihydroartemisinin-514piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum

malaria transmission in Ouelessebougou, Mali: a four-arm, single-blind, phase 2/3, randomised
trial. *Lancet Microbe* 2022; 3(1): e41-e51.

- 517 19. Baird JK SI SA. Evaluation of the efficacy and safety of tafenoquine co-administered with 518 dihydroartemisinin-piperaquine for the radical cure (anti-relapse) of Plasmodium vivax malaria 519 in Indonesia - INSPECTOR study. Am Soc Trop Med Hyg Virtual 2020.; 2020.
- 520 20. World Health Organization. Seasonal malaria chemoprevention with sulfadoxine-

521 pyrimethamine plus amodiaquine in children: A field guide, 2013.

522 21. Meerstein-Kessel L, Andolina C, Carrio E, et al. A multiplex assay for the sensitive
523 detection and quantification of male and female Plasmodium falciparum gametocytes. *Malar J*524 2018; **17**(1): 441.

525 22. Bousema T, Okell L, Shekalaghe S, et al. Revisiting the circulation time of Plasmodium 526 falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte

- 527 carriage and the effect of gametocytocidal drugs. *Malar J* 2010; **9**: 136.
- 528 23. Feachem RGA, Chen I, Akbari O, et al. Malaria eradication within a generation:
- 529 ambitious, achievable, and necessary. *Lancet* 2019; **394**(10203): 1056-112.
- 530 24. Group WGS. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria
- 531 following treatment with artemisinin combination therapy: a systematic review and meta-
- analysis of individual patient data. *BMC Med* 2016; **14**: 79.

533 Roth JM, Sawa P, Omweri G, et al. Plasmodium falciparum gametocyte dynamics after 25. 534 pyronaridine-artesunate or artemether-lumefantrine treatment. Malar J 2018; 17(1): 223. 535 26. Meibalan E, Barry A, Gibbins MP, et al. Plasmodium falciparum Gametocyte Density and 536 Infectivity in Peripheral Blood and Skin Tissue of Naturally Infected Parasite Carriers in Burkina 537 Faso. J Infect Dis 2021; 223(10): 1822-30. 538 Sutanto I, Soebandrio A, Ekawati LL, et al. Tafenoquine co-administered with 27. 539 dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): 540 a randomised, placebo-controlled, efficacy and safety study. Lancet Infect Dis 2023. 541 28. Webster R, Mitchell H, Peters JM, et al. Transmission Blocking Activity of Low-dose 542 Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. Clin 543 Infect Dis 2023; 76(3): 506-12.

54429.Centers for Disease Control and Prevention (CDC). Tafenoquine Approved for Malaria

545 Prophylaxis and Treatment. 2022. <u>https://wwwnc.cdc.gov/travel/news-</u>

546 <u>announcements/tafenoquine-malaria-prophylaxis-and-treatment</u>.

547 30. Witmer K, Dahalan FA, Delves MJ, et al. Transmission of Artemisinin-Resistant Malaria

548 Parasites to Mosquitoes under Antimalarial Drug Pressure. *Antimicrob Agents Chemother* 2020;

549 **65**(1).





Days after treatment start













